A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Prostate tumor heterogeneity and biopsy undersampling pose challenges to accurate, individualized risk assessment for men with localized disease.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Eur Urol

Title: European urology

Publisher: Elsevier BV

ISSN (Electronic): 1873-7560

ISSN (Print): 0302-2838

Publication date (Electronic): Sep 2014

Volume: 66

Issue: 3

Affiliations

[1 ] Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: kleine@ccf.org.

[2 ] Department of Urology, University of California, San Francisco and UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.

[3 ] Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.

[4 ] Department of Urology, University of California, San Francisco and UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.

[5 ] Genomic Health, Inc., Redwood City, CA, USA.

[6 ] Department of Urology, University of California, San Francisco and UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

[7 ] Department of Pathology, University of California, San Francisco, San Francisco, CA, USA; Genomic Health, Inc., Redwood City, CA, USA.

[8 ] Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA.

[9 ] Department of Urology, University of California, San Francisco and UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. Electronic address: pcarroll@urology.ucsf.edu.

Article

Publisher Item ID: S0302-2838(14)00414-X

DOI: 10.1016/j.eururo.2014.05.004

PubMed ID: 24836057

SO-VID: 91ad2972-e1e8-4b70-9fa3-8c735dde4339

History

Keywords: Clinical utility,Clinical validation,Gene expression,Genomic Prostate Score,Heterogeneity,Prostate neoplasms,Surgical pathology

Data availability:

Keywords: Clinical utility, Clinical validation, Gene expression, Genomic Prostate Score, Heterogeneity, Prostate neoplasms, Surgical pathology

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

Read this article at

Abstract

Related collections

Measurement of Glucocorticoid Receptor Signaling in Major Depression

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 111

Cited by 200